

## Without Cirrhosis

**TABLE 130: SVR GENOTYPE 3 WITHOUT CIRRHOSIS TREATMENT-NAIVE: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS —RANDOM EFFECTS MODEL**

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24	PR48	1.32 (1.18 to 1.47)	22.44 (13.18 to 30.40)
DCV12 + SOF12		1.38 (1.23 to 1.53)	26.49 (17.39 to 33.81)
DCV12 + SOF12	SOF24 + RBV24	1.04 (0.95 to 1.14)	4.10 (−4.61 to 11.81)
Random effect model	Residual deviance	9.206 vs. 10 data points	
	Deviance information criteria	59.551	
Fixed effect model	Residual deviance	9.193 vs. 10 data points	
	Deviance information criteria	59.126	

Cri = credible interval; DCV = daclatasvir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.